

# Index

**Note:** The letters ‘f’ and ‘t’ following locators refer to figures and tables respectively.

## A

- ACTION, *see* The Adjuvant Treatment in Ovarian Neoplasm (ACTION)
- Adjuvant chemotherapy, 3–5
- The Adjuvant Treatment in Ovarian Neoplasm (ACTION), 3
- Adoptive T-cell therapy, 213–214
- Advanced-stage (IIb–IV) ovarian cancer, 4–7
- AGO and GOG-158 trials, 4
  - first-line chemotherapy, randomised trials, 6f
  - GOG-111 and EORTC–NCIC OV-10 trials, 4
  - intraperitoneal chemotherapy, phase III trials, 5–6
  - treatment-related complications, 6–7
  - JGOG phase III trials in women, 4
  - non-platinum cytotoxic agents, role, 5
  - paclitaxel with carboplatin, therapy, 5
- Advanced-stage serous tumours, 14
- Advances in treatment of ovarian cancer
- advanced-stage serous tumours, study
  - low-grade/high-grade, 14
  - chemotherapy, 14–16
  - alternative agents targeting tubulin, 15
  - folate metabolism, examination, 16
  - NAB-paclitaxel, treatment of metastatic breast cancer, 15
  - paclitaxel poliglumex (CT-2103), phase III trial, 15
  - taxanes, mechanism of action, 14–15
  - trabectedin, DNA-targeting agent, 15
- hormonal therapy, 18
- immunotherapy, 18
- molecularly-targeted therapies, 18–21
- angiogenesis inhibitors, 18–20
  - critical signalling molecules, 21
  - EGFR and HER2 inhibitors, 20–21
  - PARP inhibitors, 20
  - mucinous tumours, interventions, 14
  - resistance-modifying agents, 16–17
  - targeted therapy agents, 13, 13f
- Affymetrix<sup>®</sup> array, 37, 40, 43
- Aflibercept, 58
- $\alpha$ -FR, 246
- $\alpha$ -FR-targeted treatment for ovarian cancer
- biology of FR, 245–248
  - FR and cancer, 246–248
  - FR isoforms and distribution in normal tissues, 246
- immunotherapies directed towards  $\alpha$ -FR, 249–251
- EC17 administration, phase I study, 251
  - MORAb-003, clinical trials, 250
  - MOv18, phase I studies, 249–250
- patient selection, 249
- imaging techniques, benefits, 249
- small molecule therapies directed to the  $\alpha$ -FR, 251–254
- antifolates, 251–253
  - drug carriers conjugated to folate, 254
  - therapeutic agents conjugated to folate, 253–254
- AKT inhibitors, 77, 80–87, 81t–82t
- allosteric inhibitors, 83–85
  - ATP-competitive inhibitors, 80–83
  - GSK690693, 80–83
  - lipid-based inhibitors, 86–87
  - peptide-based inhibitors, 85
- AKT-in, peptide-based inhibitor, 82t, 85
- AKT pathway in ovarian cancer, targeting
- AKT inhibitors
  - allosteric inhibitors, 83–85
  - ATP-competitive inhibitors, 80–83
  - lipid-based inhibitors, 86–87
  - peptide-based inhibitors, 85
- efficacy and toxicity, 80
- inhibition of, 79–80

- AKT pathway in ovarian cancer (*cont.*)  
 PI3K/AKT pathway, 74–76  
 aberrations in, 77–78  
 in platinum resistance, role of, 78–79  
 PI3K and mTOR inhibition, 87–88  
 mTOR inhibitors, 88  
 PI3K inhibitors, 87–88
- AKT/protein kinase B signalling inhibitor-2 (API-2), 81t, 84–85
- Alkylphospholipids (APLs), 86
- Allosteric inhibitors, 83–85  
 AKTi-1, AKTi-2, AKTi-1,2, 85  
 API-2, 84–85  
 MK-2206, 83–84
- AMG 102, 178
- AMG 386, 63, 176
- AMG 479, 174
- Angiogenesis, 18, 21, 37, 52–54, 63, 96–99, 137, 139t, 141f, 145f, 146–150, 176, 179, 206, 228t, 235–236  
 in ovarian cancer, 53–54  
 as a therapeutic target, 52–53
- Angiogenesis inhibitors, 18–20  
 bevacizumab, phase II trials, 19  
 bevacizumab with carboplatin/paclitaxel, phase III trials, 19  
 VEGFR TKIs, clinical trials, 19–20  
 VEGF Trap, phase II trial, 19
- ‘Angiogenic switch,’ 52, 98, 149
- Anti-angiogenic compounds, 63–64  
 angiotensins and ephrin receptor tyrosine kinase, 63–64  
 safety profile of, 64–65  
 thalidomide, 63
- Anti+CA-125 monoclonal antibody, 210
- Antifolates, 16, 246, 251–253  
 ONX 0801, role in tumor selectivity, 252  
 ONX 0801 *vs.* classical antifolate uptake in tumour/normal cells, 252f
- Anti-HER2 therapy, 169–170
- Anti-idiotype antibody (ACA-125), 210
- Anti-IL-6 therapy, 152
- Anti-VEGF agents  
 aflibercept  
 phase I dose-finding study, 58  
 phase II double-blind study, 58  
 phase III study, 58  
 side effects, 58  
 bevacizumab (avastin), 54–58  
 with carboplatin and paclitaxel in the first-line setting, 57–58  
 with chemotherapy in patients with recurrent ovarian cancer, 56–57  
 in patients with recurrent ovarian cancer, 54–56  
 combination with multi-target therapy, 62  
 EGF and VEGF, downstream signalling pathways, 62  
 resistance to antiangiogenic therapies, hypotheses, 62  
 vertical blockade, strategy to enhance efficacy, 62  
 RTK inhibitors, 59–62  
 identified in relapsed ovarian cancer, 59  
 maintenance therapy, phase II study with BIBF 1120, 59  
 VDAs, 62–63
- API-2, *see* AKT/protein kinase B signalling inhibitor-2 (API-2)
- Aplasia Ras homolog member I (ARHI), 237
- APLs, *see* Alkylphospholipids (APLs)
- Arginase, 206, 208–209
- ARHI, *see* Aplasia Ras homolog member I (ARHI)
- ATP-competitive inhibitors, 80–83, 85, 88
- 5-azacytidine, 190, 193–194
- AZD0530, 101, 102t, 103
- AZD6244, 14
- B**
- Base excision repair (BER), 110, 118, 122–123, 266
- B-cell stimulatory factor 2 (BSF-2), 142  
*See also* IL-6
- Bevacizumab, 5, 12t, 19, 23–24, 52, 54–58, 62, 64–65, 101, 119t, 179, 210, 235, 272  
 with carboplatin and paclitaxel in the first-line setting, 57–58  
 with chemotherapy in patients with recurrent ovarian cancer, 56–57  
 in patients with recurrent ovarian cancer, 54–56
- $\beta$ -FR, 246
- $\beta$ -tubulin, mutations in, 259–260
- Biology of FR, 245–248  
 FR and cancer, 246–248  
 $\alpha$ -FR and Cav-1 expression, relationship, 248  
 frequency of  $\alpha$ -FR expression in ovarian carcinomas, 247t  
 frequency of  $\alpha$ -FR expression in solid tumors, 247t  
 $\alpha$ -FR expression in ovarian cancer patients, 248  
 FR isoforms and distribution in normal tissues, 246

- Bosutinib, 101, 102t
- BRCA** dysfunction in ovarian cancer, 109–128
- BRCA1/BRCA2*/familial ovarian cancer, 116
  - BRCAness for PARP inhibitor therapy, 116–117
  - BRCAness in sporadic tumours, 118
  - clinical trials landscape in 2010, 127–128
  - combination PARP inhibitor clinical trials, 119t–120t, 122–123
  - DNA damage and repair, 110
  - DNA DSB repair, *BRCA1/BRCA2* genes in, 111–113
  - mechanism-based resistance to PARP inhibitors, 126–127
  - PARP and SSB repair/BER, 113
  - PARP inhibition in *BRCA1/BRCA2*-cancers, 114–116
  - PARP inhibitors, clinical development of, 118
  - single-agent PARP inhibitor clinical trials, 121t, 123–126
  - synthetic lethality, 114
- BRCAness**
- for PARP inhibitor therapy, 116–117
    - basal-like breast cancers, 117
    - BRCA1* hereditary tumours, 117
    - DNA replication forks, 117
    - EMSY* gene, 117
    - FANCF* (Fanconi Anaemia gene), 117
    - high-grade serous/undifferentiated tumours, 117
    - sporadic ovarian cancers, 117
    - transcriptional repressor ID4, *BRCA1*, 117
  - in sporadic tumours, 118
    - epigenetic downregulation of *BRCA1*, 118
    - functional analysis of GC, 118
    - genetic or epigenetic changes in other genes, 118
    - germline testing, 118
    - mutation detection methods, 118
    - PARP inhibitor resistance, 118
    - transcriptional or genomic signatures, 118
- C**
- Cancer cell of origin**
- definition, 224
  - identification, 227–231
    - fallopian tube fimbriae, role, 229
    - model for course of disease in relation to ovarian cancer stem cells, 231f
    - ovarian surface epithelium stem cells as reservoir, 229
    - p53 signature, 229–230
    - quiescence, 227
    - sources for epithelial ovarian cancers, 230
    - transgenic mice, “pulse–chase” experiments, 227–229
- Cancer-initiating cell, definition, 224
- Cancer progenitor cells, 223–238
- Cancer stem cells, 223–238, 228t
- definition, 224
  - identification, 225–227
    - cancer cells isolated from ascitic fluid, 225
    - CD133 vs. CD44 expression in cancer cells, 227
    - OvCSCs isolated from primary stage III serous adenocarcinomas, study, 226
    - OvCSC tumorigenicity in animal model, study, 225–226
    - prominin-1 (CD133), detection in ovarian cancers, 226–227
- Cediranib, 12t, 19, 59
- Cells in ovarian cancer immunosuppression
- dendritic cells (DCs), 205–206
  - regulatory T-cells, 205
  - tumour cells, 206–207
- Cellular membrane receptors, 165–179
- Chemokines and chemokine receptors, 146–148
- Chemotherapy, 1, 3–5, 6f, 7, 8f, 9, 11, 13–19, 21–25, 36–38, 45, 47, 53–54, 56–59, 62–64, 78–79, 87, 100, 103, 109, 111f, 113, 116, 118, 119t, 122–123, 125–126, 144, 148, 152, 169–170, 174–175, 178–179, 190, 193, 196–198, 204, 211, 214–215, 225, 248, 250, 260, 264, 266, 269–270, 272
- alternative agents targeting tubulin, 15
  - folate metabolism, examination, 16
  - NAB-paclitaxel, treatment of metastatic breast cancer, 15
  - paclitaxel poliglumex (CT-2103), phase III trial, 15
  - taxanes, mechanism of action, 14–15
  - trabectedin, DNA-targeting agent, 15
- Cisplatin, 4, 6, 6f, 8f, 16, 37, 54, 78–79, 84, 100–101, 119t, 126–127, 144, 150, 193, 198, 226, 234, 250, 264
- Clear cell tumors, 14, 38–39, 77, 136, 247t
- c-Met, 177–178

- CN, *see* Contortrostatin (CN)  
 CNTO-95, 177  
 Combination PARP inhibitor clinical trials, 119t–120t, 122–123  
   AG014699, 122  
   base excision repair, 123  
   chemotherapies/radiotherapy and targeted agents, 122  
   intravenous PARP inhibitor BSI-201 (BiPar Sciences), 123  
   maximum tolerated dose (MTD), 122  
   neutropenia, 123  
   PARP inhibitory dose (PID), 122  
   pharmacokinetics (PK), 122  
   randomized Phase II trial, 123  
   RECIST partial responses, 122  
   sporadic triple negative breast cancer, 122–123  
   synthetic lethality, 123  
 Combretastatin, 63  
 Contortrostatin (CN), 150  
*c-Src*, 96  
 CTLA-4 antibody therapy, 214  
 CTLs, *see* Cytotoxic T-lymphocytes (CTLs)  
 CVX-060, 176  
 Cyclooxygenases and ovarian cancer, 137–138  
   isoforms of, functions, 137  
   NSAIDs as preventative agents, 138  
 Cytokines/chemokines in ovarian cancer, 139t, 206  
   chemokines and chemokine receptors, 146–148  
 IL-6, 142–144  
   biological functions, 142t  
   chemoresistance mechanisms, 144  
   IL-6 function and the EOC tumour microenvironment, 145f  
   inhibition of IL-6 gene expression, results, 143  
   role in modulating inflammatory processes, 142–143  
   treatment with anti-IL-6 in combination with anti-IL-1 therapy, 143  
 IL-1 $\beta$ , 145–146  
 integrins, 150–151  
   CN treatment of integrins, 150  
   LM609, *in vivo* study, 150–151  
    $\alpha\beta 3$  integrin, role in angiogenesis, 150  
    $\alpha v$  integrins, role in chemoresistance, 150  
   *in vivo* anti-VCAM-1 therapy in mice, results, 151  
 MCSF-1, 148–149  
 MIF, 149  
 ovarian immune microenvironment, role in, 208  
   IDO/arginase, role in immune suppression, 208–209  
   TAAs, role, 209  
 TNF- $\alpha$ , 138–142  
   effects of curcumin, 142  
   efficacy of NF- $\kappa$ B inhibition in EOC, 142  
   tissue culture studies, 140  
   TNFR1 signalling, role, 138–139  
   tumourigenic actions of, 141f  
   *in vitro* organoid model of HOSE cells with TNF, study, 139  
 Cytotoxic T-lymphocytes (CTLs), 204, 207
- D**  
 Dasatinib, 14, 21, 101, 102t, 174, 215  
 DCs, *see* Dendritic cells (DCs)  
 DC therapy, 213  
 Dendritic cells (DCs), 134, 146, 205–206, 210t, 213  
   immunosuppression by macrophages, 206  
   CSF-1-deficient *op/op* mouse model, study, 206  
 MDSCs, role in ovarian cancer, 205–206  
   subtypes, 205  
 Dictyostatin, 270  
*Discoderma dissolute*, 270  
 Discodermolide, 270–271  
 Discovery of novel targets  
   bioinformatic analysis, 40–43  
   signaling pathways characterizing tumors, 40–42  
   future directions, 47  
   screening for novel therapeutic targets, 48f  
   genomics, 37–38  
   oligonucleotide microarray analysis, 37  
 heterogeneity in ovarian tumors, genomic analysis, 39–40  
   for LMP tumors, late-stage, high-grade cancers, and OSE, 41f  
 high-grade ovarian cancers, 43–47  
   hierarchical clustering of advanced-stage adenocarcinomas, 43–44, 44f  
   integrin-mediated signaling by MAGP2, 44–47, 45f, 46f  
 historic perspective of drug development, empirical approaches, 36–37  
 application of molecular technology, 37

- methotrexate treatment of gynecologic malignancies, 36
    - “one size fits all,” ovarian cancer, 37
    - platinum-based agents, properties, 36–37
  - tumor histology, 38–39
    - clear cell and mucinous tumors, 38
    - gene expression profiles of tumors, comparison, 38–39
    - papillary serous and endometrioid tumors, 38
    - PCA of ovarian and endometrial cancers, 39, 40f
  - Disintegrin, 150
  - DLT, *see* Dose-limiting toxicity (DLT)
  - DNA damage and repair, 110
    - base modifications, 110
    - BER, 110
    - double-strand breaks (DSBs)
      - HR, 110
      - NHEJ, 110
      - repair pathways, 111f
      - translocations, 110
    - intrastrand and interstrand cross-links, 110
    - mismatch repair pathways, 110
    - nucleotide excision repair, 110
  - DNA DSB repair
    - BRCA1* genes in, 111–113
      - chromosome instability, 112
      - GC and SSA, reduced, 112
      - RAD51/BARD1, 112
    - BRCA2*, genes in
      - chromosome instability, 112
      - DNA-binding domain (DBD), 113
      - genomic stability, 112
      - quadri-radial and tri-radial chromosomes, 112
      - RAD51-dependent DNA strand invasion, 113
      - SSA pathway, 112
    - cells deficient in *BRCA1* or *BRCA2*
      - function, 112f
    - heterozygous germline mutations, 111
    - transcription and cell cycle regulation, 111–112
  - DNA methylation in ovarian cancer
    - BRCA1/MLH1* methylation, response to platinum chemotherapy, 193
    - compounds mediating DNA demethylation, 193–194
    - 5-azacytidine, 193–194
    - cytidine ribose nucleoside, disadvantage, 194
    - variation in drug metabolism of DNMT inhibitors, impact, 194
    - prognostic/predictive biomarkers, 193
    - transcriptional silencing, 193
    - use of DNMT inhibitors in solid tumours, 194–196
      - combined decitabine/carboplatin treatment, lack of efficacy, 195–196
      - phase I trial of carboplatin and decitabine, 195
  - DNA methyltransferase (DNMT) inhibitors, 191–196, 199
  - Dormancy, 237
  - Dose-limiting toxicity (DLT), 123–124, 179, 253, 269–270, 269t
  - Double-strand breaks (DSBs), 110
    - homologous recombination (HR), 110
    - gene conversion (GC), 110
    - single-strand annealing (SSA)
      - sub-pathways, 110
    - non-homologous end-joining (NHEJ), 110
      - G<sub>0</sub>/G<sub>1</sub>/S phases of cell cycle, 110
      - translocations, 110
    - repair pathways, 111f
    - translocations, 110
  - Dynamic instability of microtubules, 260
- ## E
- Early-stage ovarian cancer (I–IIa), 3–4
    - adjuvant chemotherapy trials, results, 3
    - biologic profile/surgical staging, 3–4
    - GOG-157 trial, 3
  - EGFR, *see* Epidermal growth factor receptor (EGFR)
  - EGFR and HER2 inhibitors, 20–21
  - EGFR ligands, 167, 171
  - “Embryonal-rest hypothesis,” 223
  - Ephrin receptor tyrosine kinase, 63
  - Epidermal growth factor receptor (EGFR), 12t, 18, 20–21, 56, 62, 65, 73, 148, 150, 167–172, 174–176, 210–211
  - Epigenetic code, 190, 199
  - Epigenetic deregulation
    - epigenetic code, role, 190
    - mechanisms of, 190
  - Epigenetic features of cancer cells, 236–237
  - Epigenetic therapies
    - DNA methylation, target in ovarian cancer
      - compounds mediating DNA demethylation, 193–194
      - use of DNMT inhibitors in solid tumours, 194–196
    - histone acetylation and HDAC inhibitors

- Epigenetic therapies (*cont.*)
- combined HDAC and chemotherapeutic treatments, 198
  - HDAC inhibitors as single agent, 197
  - improved targeting of epigenetic therapies, 198–199
  - DNMT/HDAC inhibitors, lack of specificity, 199
  - HDAC inhibitors in solid tumour setting, issues, 198
  - mechanisms of epigenetic deregulation, 190
- Epithelial-to-mesenchymal transition (EMT), 165–179
- MET, reverse process, 166
  - morphology/protein expression differences, epithelial/mesenchymal cells, 166–167, 167f
  - role of growth factors, 166–167
  - role in malignant progression, 166
- Epothilone B derivatives, 268
- ixabepilone (BMS), 268–270
  - patupilone (Novartis), 268–269
  - sagopilone (Schering), 268, 270
- Epothilone D compounds, 270–271
- Epothilones, 268
- characteristics in clinical trials, 268t
  - classification, 268
  - therapeutic advantage, 268
- F**
- FAK, *see* Focal adhesion kinase (FAK)
- Fallopian tube fimbriae, 229, 231
- Familial ovarian cancer
- BRCA1/BRCA2*, 116
  - hereditary germline mutations, 116
  - platinum-based chemotherapy, 116
  - screening and prophylactic surgical measures, 116
- FGF, *see* Fibroblast growth factor (FGF)
- Fibroblast growth factor (FGF), 22, 53, 166, 206
- Focal adhesion kinase (FAK), 44, 97f, 99, 101, 103, 167, 169, 175, 178, 264
- Folate-conjugated drug carriers, 254
- Folate–drug conjugates, 253–254
- clinical trials
    - BMS-753493, 253
    - EC145, 253
    - EC0225, 253
  - transcytosis in renal proximal tubule cells, 253–254
- Folate receptor (FR), 21, 209, 211, 245–255
- FR, *see* Folate receptor (FR)
- $\gamma$ -FR, 246
- FR isoforms, 246
- G**
- Gastrointestinal perforation (GIP), 19, 22, 54, 56–57, 64
- GCOS, *see* GeneChips Operating Software (GCOS)
- GDC-0449, 179
- Gemcitabine, 5, 9, 10t, 11, 16–17, 19, 37, 52, 57–58, 87, 100, 119t–120t, 123, 170, 272
- GeneChips Operating Software (GCOS), 37
- Gene conversion (GC), 110, 111f
- GIP, *see* Gastrointestinal perforation (GIP)
- Gorlin Syndrome, 179
- Gynecologic malignancies, 36, 224
- Gynecologic Oncology Group (GOG), 2–7, 11, 14–15, 19, 22–23, 57–58, 171–172
- H**
- HDAC inhibitors, 196–198
- classes, targets and clinical trial status, 196t
  - and histone acetylation
    - combined HDAC and chemotherapeutic treatments, 198
    - HDAC inhibitors as single agent, 197
- Hepatocyte growth factor/scatter factor (HGF/SF), 177
- HER, *see* Human epithelial receptors (HER)
- HER2, *see* Human epidermal growth factor 2 receptor (HER2)
- High-grade ovarian cancers, 14, 20, 43–47
- High-grade serous tumours, 3, 14
- Histone deacetylase (HDAC) inhibitors, 190, 196–198
- Homologous recombination (HR), 110
- gene conversion (GC), 110
  - recombinase function of RAD51, 110
  - sister chromatid, 110
  - SSA sub-pathways, 110
    - annealing of DNA strands, 110
    - pathway of mutagenesis, 110
    - in S–G2 phases of the cell cycle, 110
- Hormonal therapy, 18
- HOSE cells, *see* Human ovarian surface epithelial (HOSE) cells
- HOX* genes, 230
- Human epidermal growth factor 2 receptor (HER2), 12t, 18, 20–21, 73, 80, 147, 167–168, 170–172, 175–176, 209, 211–212, 215
- Human epithelial receptors (HER), 167–173

- See also* Human epidermal growth factor 2 receptor (HER2)
- Human ovarian surface epithelial (HOSE) cells, 139
- Hypothyroidism, 65
- I**
- ICON, *see* The International Collaborative Ovarian Neoplasm (ICON)
- IGF2, *see* Insulin-like growth factor 2 (IGF2)
- IGFR, *see* Insulin-like growth factor receptor (IGFR)
- IL-6, 98, 134–135, 139t, 140, 142–144, 145f, 146, 148–149, 151–152, 205–207, 210t
- Imatinib, 21, 25, 38, 59, 73, 215, 233
- Immunology and immunotherapy in ovarian cancer
- cells involved in ovarian cancer
    - immunosuppression
      - dendritic cells (DCs), 205–206
      - regulatory T-cells, 205
      - tumour cells, 206–207
    - CTLs/TILs, role, 204
    - cytokines, 208–209
    - immune responses after chemotherapy, 214–215
    - immunomodulatory molecules
      - CTLA-4, role in conversion of CD4<sup>+</sup> cells into Tregs, 207–208
      - PDL1 expression, 207
      - tumor suppression by L-selectin, 206
      - tumor suppression by
        - TCR complex, 206
  - immunotherapeutic strategies
    - antibodies, 210–212
    - cellular therapies, 213–214
    - other strategies, 214
    - peptide vaccines, 212–213
    - interferon alpha, effects, 204
    - treatment of, surgery and chemotherapy, 203–204
- Immunotherapeutic strategies in ovarian cancer
- antibodies, 210–212
    - ACA-125, clinical trials, 211
    - anti+CA-125 monoclonal antibody, 210
    - infiximab, clinical trials, 211–212
    - MoAbs, 210
    - MUC-1, 212
    - treatment with oregovomab, clinical trials, 210–211
  - cellular therapies
    - adoptive T-cell therapy, 213–214
    - dendritic cell (DC) therapy, 213
    - immunosuppressive processes in cancer, 210t
    - other strategies
      - CTLA-4 antibody therapy, 214
    - peptide vaccines, 212–213
      - antigen-specific immunotherapy,
        - Cochrane review of, 213
        - HER2/neu, phase I/II trials, 214
        - multi-peptide vaccine, advantage, 214
        - NY-ESO-1, phase I clinical trial with Freund's adjuvant, 213
  - Immunotherapy, 18, 203–215, 254
  - Inflammatory cytokines, 136–138, 139t, 146, 149, 207, 210t
  - Inflammatory pathways in EOC, targeting clinical trials
    - anti-IL-6 therapy, 152
    - targeting TNF/TNFR and downstream signalling, 151–152
  - cyclooxygenases and ovarian cancer, 137–138
  - cytokines and chemokines in ovarian cancer
    - chemokines and chemokine receptors, 146–148
    - IL-6, 142–144
    - IL-1 $\beta$ , 145–147
    - integrins, 150–151
    - MCSF-1, 148–149
    - MIF, 149
    - TNF- $\alpha$ , 138–142
  - ovarian cancer-related inflammation, 135–137
- Insulin-like growth factor 2 (IGF2), 237
- Insulin-like growth factor receptor (IGFR), 173–175
- AMG 479, 174
  - binding of ligand to IGF-IR, 173
  - CP-751,871, phase I trial, 174
  - IGF-IR inhibition, role in cancer treatment, 175
  - IGF signaling pathway, role in follicular development, 173
  - NVP-AEW 541, evaluation, 175
- Integrins, 14, 97f, 134, 150–151, 169, 173, 175–177
- The International Collaborative Ovarian Neoplasm (ICON), 3, 19
- Intraperitoneal (IP) chemotherapy, 5–6
- Intraperitoneal paclitaxel therapy, 272
- Ixabepilone, 15, 268–269

**K**

Kinesin spindle protein (KSP), 15  
 KSP, *see* Kinesin spindle protein (KSP)  
 KX2-391, 101, 102t

**L**

Lapatinib, 169, 171  
 Lauimalide, 271  
 Ligand-directed VDAs, 62  
 Lipid-based inhibitors, 86–87  
   APLs, 86  
   perifosine, 86–87  
   PIAs, 86  
 LMP tumors, 39–43, 41f  
 Low-grade invasive adenocarcinoma, 14  
 LY294002, 78, 86–87

**M**

Macrophage colony-stimulating factor (MCSF-1), 148–149  
 Macrophage migration inhibitory factor (MIF), 149  
 MAPs, *see* Microtubule-associated proteins (MAPs)  
 MCSF-1, *see* Macrophage colony-stimulating factor (MCSF-1)  
 MDSCs, *see* Myeloid-derived suppressor cells (MDSCs)  
 Microtubule-associated proteins (MAPs), 259  
 Microtubule catastrophe, 260, 264  
 Microtubules  
   and the cell cycle, 265–267  
     mechanistic insights into taxane response, 266–267  
     pharmacodynamic target of taxanes, 259–261  
     backbone structure and components, 259  
     dynamic instability, 260  
     microtubule polarity, 259–260  
     taxane resistance and tubulin function, 260–261, 261f  
   stability, mechanism of resistance  
     acetylation and detyrosination, 263–264  
     extracellular/intracellular effectors, 262  
     stathmin, predictive factor for taxane resistance, 264  
 MIF, *see* Macrophage migration inhibitory factor (MIF)  
 Mixed Müllerian tumours, *see* High-grade serous tumours  
 MK-2206, 81t, 83–84  
 MoAbs, *see* Monoclonal antibodies (MoAbs)  
 Molecularly targeted therapy

cellular membrane receptors, 165  
 EGFR/HER, 167–173  
   anti-HER2 therapy with trastuzumab and pertuzumab, 169–170  
   cetuximab, phase II study with carboplatin, 170–171  
   embryogenesis, role in, 168–169  
   phase II trials of EGFR inhibitors in relapsed ovarian cancer, 169t  
   phase I study of lapatinib with carboplatin, 171  
   role of gefitinib in a phase II GOG trial, 172  
 EMT  
   morphology/protein expression alterations, epithelial/mesenchymal cells, 166–167, 167f  
 EMTs/METs, role in growth/spread of malignant disease, 166  
 epithelial-to-mesenchymal transition, 166–167  
   MET, reverse process, 167  
   role in malignant progression, 166  
 Hedgehog signaling  
   importance in patients with Gorlin syndrome, 179  
   PCTH1, 179  
   phase II trial of GDC-0449 as maintenance therapy, 179  
   phase I results of GDC-0449, 179  
   role in EMT/embryonic development, 179  
 IGFR, 174–175  
 integrins, 175–178  
   angiopoietins/TIE-2 receptor, role in tumor angiogenesis, 176  
   E-cadherin expression, 175–176  
   EGFR inhibition, study in xenograft animal models, 176  
   function of integrin receptors, 175  
   vitaxin and CNTO-95, 177  
   volociximab, preclinical testing/results, 177  
 targeting c-Met, 177–178  
   c-Met protein expression by immunohistochemistry, detection, 178  
   HGF/c-Met signaling pathway, 177  
   ligand binding, effects, 177  
   XL-880, phase II testing, 178  
 Monoclonal antibodies (MoAbs), 210  
 MTOR inhibitors, 88



- AZD8055 and OSI-027, phase I and II trials, 88
- temsirolimus/everolimus, treatment of RCC, 88
- Mucinous tumors, 38
- Myeloid-derived suppressor cells (MDSCs), 205–206
- N**
- NAB paclitaxel, *see* Nanoparticle albumin-bound (NAB) paclitaxel
- Nanoparticle albumin-bound (NAB) paclitaxel, 15, 272
- Neuropilin-1, 53
- Neuropilin-2, 53
- Newly diagnosed ovarian cancer, existing treatments
- advanced-stage (IIb–IV) ovarian cancer, 4–7
  - early-stage ovarian cancer (I–IIa), 3–4
  - surgical staging, importance, 2–3
- Non-coding RNAs, 192
- Non-homologous end-joining (NHEJ), 89, 110, 111f, 112–113
- Norepinephrine, 98
- Novel anti-angiogenic therapies in ovarian cancer
- angiogenesis as a therapeutic target, 52–53
    - angiogenic switch, functioning of, 52–53
    - physiological/pathological angiogenesis, 52
    - tumour neovascularisation, pathways, 53
    - VEGF, prototypic pro-angiogenic growth factor, 53
  - angiogenesis in ovarian cancer
    - inhibition mechanisms, 53–54
    - VEGF, role in ovulatory cycle, 53
  - anti-angiogenic compounds, 63–64
    - angiopoietins and ephrin receptor tyrosine kinase, 63–64
    - thalidomide, 63
  - anti-VEGF agents
    - afibercept, 58
    - bevacizumab (avastin), 54–58
    - combination with multi-target therapy, 62
    - RTKs, 59
    - VDAs, 62–63
  - future trials and tribulations, 65–68
    - cost and affordability, 67
    - development of surrogate biomarkers, 65
    - identification of effective surrogate endpoints, 65–66
  - platinum–paclitaxel treatment, standard of care, 51–52
  - safety profile of anti-angiogenic agents, 64–65
    - diarrhoea, oral RTK inhibitors, 65
    - hypertensive effects, 64–65
    - hypothyroidism, 65
    - reversible posterior leucoencephalopathy, 65
    - risk of GIP with bevacizumab, 64
    - tracheo-oesophageal fistulae, 65
- NY-ESO-1, 209, 212–213
- O**
- Oligonucleotide microarrays, 37
- ONX 0801, 251–253, 252f
- Optimal cytoreduction (optimal debulking), 3
- Oregovomab, 12t, 18, 210–211
- Ovarian cancer immunology and immunotherapy
- cells involved in ovarian cancer
    - immunosuppression
      - dendritic cells (DCs), 205–206
      - regulatory T-cells, 204
      - tumour cells, 204–205
  - CTLs/TILs, role, 204
  - cytokines, 205–206
  - immune responses after chemotherapy, 214–215
  - immunomodulatory molecules
    - CTLA-4, role in conversion of CD4<sup>+</sup> cells into Tregs, 207–208
    - PDL1 expression, 207
    - tumor suppression by L-selectin, 208
    - tumor suppression by TCR complex, 208
  - immunotherapeutic strategies
    - antibodies, 207–208
    - cellular therapies, 213–214
    - other strategies, 214
    - peptide vaccines, 212–213
  - interferon alpha, effects, 204
  - treatment of, surgery and chemotherapy, 204–205
- Ovarian cancer progenitor/stem cells and cells of origin, identification
- ovarian cancer cells of origin, 227–231
  - ovarian cancer stem cells, 225–227
  - critical questions to be addressed, 238
  - historical perspective, 223–224
  - “embryonal-rest hypothesis” (Virchow and Cohnheim), 223

- Ovarian cancer progenitor (*cont.*)
- experimental study by Southam and Brunschwig, 223–224
  - terminology
    - cancer cell of origin, definition, 224
    - cancer-initiating cell, definition, 224
    - cancer stem cells, definition, 224
    - stem cells, 224
  - therapeutic potential, 231–237
    - cell surface markers, 232–233
    - chemotherapeutic agents, role, 232–233
    - epigenetic features, 236–237
    - gene expression profiles and networks, 233–234
    - growth characteristics, 234–235
    - niche, 235–236
    - potential contribution of OvCSCs to disease recurrence, 232f
    - treatment/outcomes/recurrent disease, theoretical importance, 224–225
- Ovarian cancer-related inflammation, 135–137
- anti-IL-6 therapy
    - phase II study of CNTO328, 152
  - targeting TNF/TNFR and downstream signalling, 151–152
    - deletion of TNF receptors, resistance to carcinogenesis, 151
    - infliximab, clinical efficacy, 151–152
    - infliximab, effects on plasma and ascitic cytokine levels in advanced EOC, 152
    - phase II clinical study of etanercept, 151
- Ovarian surface epithelium stem cells, 229
- P**
- Paclitaxel
- administration, alternative strategies, 271–272
  - dose intensification strategies, 272
  - nab-paclitaxel, importance, 272
  - pharmacokinetic behaviour, clinical implications, 271
  - taxane treatment, 272
  - weekly dosing with paclitaxel, trials/feasibility study, 271–272
  - resistance mechanisms in cancer cells, 260, 261f
- Paclitaxel poliglumex (CT-2103), 15, 23
- Papillary serous and endometrioid tumors, 38, 246
- PARP, *see* Poly(ADP) ribose polymerase (PARP)
- PARP inhibitors, 20
- Pathological angiogenesis, 52
- Patupilone, 15, 268–269, 269t
- Pazopanib E-7080, 59
- PCA, *see* Principal component analysis (PCA)
- PD1, *see* Programmed death-1 molecule (PD1)
- PDGF, *see* Platelet-derived endothelial cell growth factor (PDGF)
- PDL1/L2, *see* Programmed death ligands 1 and 2 (PDL1/L2)
- Pemetrexed, 16, 251, 252f
- Peptide-based inhibitors, 80, 85
- Peptide vaccines, 212–213, 215
- Perifosine, 81t, 86–87
- Pertuzumab, 12t, 20, 169–170, 178, 211
- Phosphatidylinositol ether lipid analogues (PIAs), 86
- Physiological angiogenesis, 52
- PIAs, *see* Phosphatidylinositol ether lipid analogues (PIAs)
- PI3K/AKT pathway, 74–76, 87
- aberrations in, 77–78
  - key therapeutic targets/downstream effectors, 75f
  - in platinum resistance, role of, 78–79
    - cisplatin and carboplatin, role in apoptosis, 78
    - cisplatin resistance by activation of AKT2, 78
- PI3K inhibitors, 78, 86–88, 90
- expression of class IA PI3K isoforms, 87–88
  - GDC-0941, phase I trials in solid tumours, 88
  - LY294002, 87
  - PI-103, antitumour activity in glioma cells, 88
  - wortmannin, 86
- Platelet-derived endothelial cell growth factor (PDGF), 22, 53, 58, 60, 208
- Platinum-based chemotherapy, 1, 5, 6f, 7, 9–12, 14, 23, 116, 125, 144, 198, 248
- Poly(ADP) ribose polymerase (PARP)
- inhibition in *BRCA1/BRCA2* cancers
    - cell lethality, 116
    - chemical inhibitors, 115
    - Chinese hamster ovary cells, 115
    - DNA replication fork, 114
    - formation of DNA lesions, 114
    - KU0058684 and KU0058948, 115
    - mutagenic NHEJ and chromosome instability, 114

- mutant cells, 115f
  - replication-associated DNA lesions, 114
  - synthetic lethal interaction, 114
  - inhibitors, clinical development of, 118
    - combination PARP inhibitor clinical trials, 118, 119t–120t
    - single-agent PARP inhibitor clinical trials, 118, 121t
  - mechanism-based resistance to, 126–127
    - CAPAN1, 126
    - cisplatin and carboplatin, 127
    - PARP inhibitor-resistant (PIR) clones, 126
    - P-glycoprotein efflux pumps, 127
  - and SSB repair/BER, 113
    - chemotherapy-induced replication fork, 113
    - histones, 113
    - poly(ADP) ribosylation, 113
    - short-patch BER pathway, 113
  - Principal component analysis (PCA), 39, 40f
  - Principle of Ockham's razor, 230
  - Programmed death ligands 1 and 2 (PDL1/L2), 207
  - Programmed death-1 molecule (PD1), 207
  - Prominin-1 (CD133), 226
  - Pseudogenes, 261–262
  - “P53 signature,” 229–230
- Q**
- Quiescence, 224, 226, 228t, 234–235, 237
- R**
- Receptor tyrosine kinases (RTKs), 52, 59–62, 65, 74, 75f, 167, 173, 176–177
  - Reduced-folate carrier (RFC), 245, 252f
  - Regulatory T-cells (Tregs), 204–205, 214
  - Relapsed (recurrent) ovarian cancer, existing treatments, 8f
    - clinical management, 7–8
    - patients, categories, 7
    - platinum-resistant disease, 11–12
      - phase II trials of targeted therapy in ovarian cancer, 12t
    - platinum-sensitive disease, 9–11
      - randomised clinical trials, 10t
    - surgical resection for relapsed ovarian cancer, 12–13
      - AGO-DESKTOP OVAR trial, 13
  - Reversible posterior leucoencephalopathy, 65
  - RFC, *see* Reduced-folate carrier (RFC)
  - Rous Sarcoma Virus (RSV), 95
  - RSV, *see* Rous Sarcoma Virus (RSV)
  - RTKs, *see* Receptor tyrosine kinases (RTKs)
- S**
- Sagopilone, 268, 269t, 270
  - Single-agent PARP inhibitor clinical trials, 121t, 123–126
    - BRCA1/2* mutation carriers
      - ABT 888 (Abbott Laboratories), 126
      - AG014699 (Pfizer), 126
      - BSI-201 (BiPar Sciences), 126
      - MK4827 (Merck & Co, Inc.), 126
    - olaparib, 124
      - analysis of, 124
      - Gynaecologic Cancer InterGroup (GCG), 124
      - phase I clinical trials, 124
      - phase II clinical trials, 125
      - ‘proof-of-concept’ trials, 125
      - RECIST, 124
      - substantial and durable antitumour activity, 124
    - radiological evidence of tumour response to olaparib, 125f
  - “Single-cell” source, cancer cell of origin, 230
  - Single-strand annealing (SSA), 110, 111f
    - annealing of DNA strands, 110
    - pathway of mutagenesis, 110
    - in S–G2 phases of the cell cycle, 110
  - Single-strand breaks (SSBs), 110, 122
  - Small molecule VDAs
    - synthetic flavonoids, 62
    - tubulin-binding agents, 62
      - cambretastatin, phase II study, 62–63
  - Sorafenib, 12t, 19, 21, 24, 59–60
  - Spheroids, 225–226, 228t, 235
  - Sporadic/familial ovarian cancers, clinical trials (2010), 127–128
    - ‘*BRCAness*’ and phenocopy *BRCA1/2*-mutated tumours despite, 127
    - homologous recombination defects, 127
      - ATM (ataxia-telangiectasia mutated), 127
      - ATR (ataxia-telangiectasia and RAD3-related), 127
      - CHK1 and CHK2, 127
      - Fanconia anaemia repair pathway, 127
      - RAD51, 127
    - olaparib, 128
  - Src inhibitors, 21, 98, 100–103, 264
    - AZD0530, 101, 102t
    - bosutinib, 101, 102t

- Src inhibitors (*cont.*)  
 dasatinib, 101, 102t  
 KX2-391, 101, 102t
- Src oncogene, inhibition of  
 angiogenic and metastatic properties of Src, 96–97, 97f  
 cell motility and disease progression, role in, 103–104  
 control of disease progression, 100  
 integrin–Src regulation of cell motility, 99  
 tyrosine phosphorylated substrates, regulators of cell migration, 99  
 current clinical trials using Src inhibitors, 101–103  
 AZD0530, 101, 102t  
 bosutinib, 101, 102t  
 combination therapy using Src inhibitor and chemotherapy, 103  
 dasatinib, 101, 102t  
 KX2-391, 101, 102t  
 phase II trial in platinum sensitive-relapsed ovarian cancer patients, 103  
 phase I trial using dasatinib with paclitaxel/carboplatin, objectives, 101  
 phase I trial with dasatinib and bevacizumab, 101–102  
 specificity of the inhibitors, 101  
 role of Src in angiogenesis and vascular permeability, 97–99  
 hypoxia, effects on Src activity, 97  
 IL-6/IL-8, role in angiogenesis, 98  
 impact on endothelial cadherin function, 98  
 therapeutic implications, 97  
 vascular disruption, study in murine stroke model, 98  
 VEGF-mediated angiogenesis, 97–98  
 RSV, cause of sarcomas, 95  
 Src and chemoresistance, 100–101  
 Src structure, 96f
- Stathmin, 260, 264
- Stem cells, *see* Cancer stem cells
- Sunitinib, 19, 59, 174
- Synthetic lethality, 114  
 constitutive genetic defect, 114  
 definition, 114  
*Drosophila* and yeast, 114  
 gene–gene interactions, 114  
 synthetic lethal screens, 114
- T**
- TAAAs, *see* Tumour-associated antigens (TAAs)
- TAK-701, 178
- Taxane response  
 chromosomal instability and, 267–268  
 novel pathways and biomarkers for, 267  
*TP53* and, mutations in, 262
- Taxol, 37, 74, 250
- Taxus brevifolia*, 37
- Thalidomide, 60, 153
- The Cancer Genome Atlas (TCGA) Project, 47
- Thymidylate synthase (TS) inhibitor, 252f, 253
- TILs, *see* Tumour-infiltrating lymphocytes (TILs)
- TNF- $\alpha$ , 134–135, 138–142, 141f, 145–147, 149, 151–153, 207–208, 210t, 211–212
- Trabectedin, 15
- Transcytosis, 253–254
- Trastuzumab, 12t, 20, 25, 69, 76, 169–170, 178, 210–211
- Treatment of ovarian cancer  
 existing treatments for newly diagnosed cancer  
 advanced-stage (IIb–IV) ovarian cancer, 4–7  
 early-stage ovarian cancer (I–IIa), 3–4  
 existing treatments for relapsed disease  
 platinum-resistant disease, 11–12  
 platinum-sensitive disease, 9–11  
 surgical resection for relapsed ovarian cancer, 12–13  
 improvements in overall survival for ovarian cancer, 1–2, 2f  
 optimal management of, 1  
 recent advances  
 chemotherapy, 14–16  
 hormonal therapy, 18  
 immunotherapy, 18  
 molecularly-targeted therapies, 18–21  
 resistance-modifying agents, 16–17  
 unmet needs  
 advanced ovarian cancer remains incurable, 21–22  
 challenges facing the optimal use of targeted therapies, 23–24  
 global resources, 24–25  
 optimal time to commence treatment for recurrent disease, 23  
 role of maintenance therapy, 22–23  
 USA/UK, incidence and mortality, 1
- Tubulin binders  
 epothilone D compounds

- tubulin-binding agents from marine organisms, 270–271
  - ixabepilone, 269–270
  - microtubules
    - and the cell cycle, 265–267
    - as pharmacodynamic target of taxanes, 259–261
    - stability, mechanism of resistance, 263–264
  - misexpression of tubulin subtypes, 262–263
    - effects of microtubule dynamics on paclitaxel resistance, 263f
  - mutations in  $\beta$ -tubulin, 261–262
    - class I tubulin, 261
    - induction of paclitaxel resistance, 261
    - pseudogenes, 261
    - study of NSCLC cases, 261–262
  - novel tubulin-binding drugs
    - epothilones, characteristics in clinical trials, 268, 269t
  - paclitaxel administration, alternative strategies, 271–272
  - patupilone, 269
  - sagopilone, 270
  - taxane response
    - chromosomal instability and, 267–268
    - mutations in *TP53* and, 262
    - novel pathways and biomarkers for, 267
  - Tumor angiogenesis, inhibition mechanisms, 53–54
  - Tumor suppression by L-selectin, 208
  - Tumour-associated antigens (TAAs), 205, 209, 212, 215
  - Tumour cells
    - ovarian cancer immunosuppression, role in cell-bound ligands, regulation of T-cell inactivation, 207
    - MHC Class I-restricted CD8+ CTLs, 206–207
    - production of inflammatory cytokines, 207
  - Tumour-infiltrating lymphocytes (TILs), 204, 209
- U**
- Unmet needs, ovarian cancer
    - global resources, 24–25
    - incurable (advanced) ovarian cancer, 21–22
    - optimal time to commence treatment for recurrent disease, 23
    - optimal use of targeted therapies, challenges, 23–24
    - role of maintenance therapy, 22–23
- V**
- Vascular disrupting agents (VDAs), 62–63
    - tumour ischaemia and necrosis, cause, 63
    - types
      - ligand-directed VDAs/small molecules, 63
  - Vascular endothelial growth factor (VEGF), 12t, 19–24, 52–62, 96–98, 97f, 103, 137, 139–140, 148–149, 176–177, 206–208, 210, 235–236
  - Vatalanib, 58
  - VDAs, *see* Vascular disrupting agents (VDAs)
  - VEGF, *see* Vascular endothelial growth factor (VEGF)
  - Vimentin, 14, 176, 227
  - Viral Src (*v-Src*), 95–96
  - Vitaxin, 177
  - Volociximab, 61, 177
- W**
- Wortmannin, 86–87
- X**
- XL-880, 178